Risk of hepatocellular carcinoma with tenofovir vs entecavir treatment for chronic hepatitis B virus: a reconstructed individual patient data meta-analysis

• Main Authors: Tan, Darren Jun Hao, Ng, Cheng Han, Tay, Phoebe Wen Lin, Syn, Nicholas, Muthiah, Mark D., Lim, Wen Hui, Tang, Ansel Shao Pin, Lim, Kai En, Lim, Grace En Hui, Tamaki, Nobuharu, Kim, Beom Kyung, Teng, Margaret Li Peng, Fung, James, Loomba, Rohit, Nguyen, Mindie H., Huang, Daniel Q.
• Other Authors: Lee Kong Chian School of Medicine (LKCMedicine)
• Format: Article
• Language: English
• Published: 2023
• Subjects: Science::Medicine; Antiviral Agents; Carcinoma
• Online Access: https://hdl.handle.net/10356/170786
• Institution: Nanyang Technological University

Conventional meta-analyses with aggregated study-level data have yielded conflicting results for the comparative effectiveness of tenofovir disoproxil fumarate vs entecavir in reducing hepatocellular carcinoma (HCC) risk among patients with chronic hepatitis B virus. Within-study heterogeneity, between-study heterogeneity, and the inability of conventional meta-analyses to capture time-to-event data were associated with these results.